Barclays PLC Buys 18,249 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Barclays PLC boosted its stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 677.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,943 shares of the company’s stock after purchasing an additional 18,249 shares during the quarter. Barclays PLC owned approximately 0.09% of Outlook Therapeutics worth $111,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its position in shares of Outlook Therapeutics by 49.2% in the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after acquiring an additional 112,812 shares during the period. XTX Topco Ltd bought a new position in Outlook Therapeutics in the 3rd quarter valued at $199,000. State Street Corp grew its position in shares of Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after purchasing an additional 21,201 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Outlook Therapeutics by 55.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock worth $275,000 after purchasing an additional 18,287 shares during the period. Finally, Christensen King & Associates Investment Services Inc. purchased a new stake in shares of Outlook Therapeutics in the third quarter worth $55,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on OTLK shares. BTIG Research decreased their target price on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. Guggenheim reiterated a “buy” rating and set a $12.00 target price on shares of Outlook Therapeutics in a research report on Friday, January 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Outlook Therapeutics has an average rating of “Moderate Buy” and an average target price of $28.07.

Outlook Therapeutics Price Performance

NASDAQ:OTLK opened at $2.04 on Friday. The company has a market capitalization of $50.82 million, a price-to-earnings ratio of -0.23 and a beta of 0.53. The business has a 50 day moving average of $2.45 and a 200 day moving average of $5.24. Outlook Therapeutics, Inc. has a 1-year low of $0.87 and a 1-year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06. As a group, sell-side analysts anticipate that Outlook Therapeutics, Inc. will post -2.25 EPS for the current year.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.